8862 related articles for article (PubMed ID: 16285075)
21. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
22. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
23. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
Vachiéry JL
Rev Med Brux; 2003 Sep; 24(4):A249-52. PubMed ID: 14606288
[TBL] [Abstract][Full Text] [Related]
24. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
25. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
Milicić D
Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
[TBL] [Abstract][Full Text] [Related]
26. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
28. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
29. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
30. Use of valsartan in post-myocardial infarction and heart failure patients.
Liu PP; Maggioni A; Velazquez EJ
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S19-22. PubMed ID: 16986231
[TBL] [Abstract][Full Text] [Related]
31. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Kageyama S
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
[No Abstract] [Full Text] [Related]
32. Valsartan. Just a second-line antihypertensive drug.
Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
[TBL] [Abstract][Full Text] [Related]
33. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
34. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Smith DG; Cerulli A; Frech FH
Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
36. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
Mazzotta G; Vecchio C
G Ital Cardiol; 1994 Jan; 24(1):59-70. PubMed ID: 8200499
[TBL] [Abstract][Full Text] [Related]
37. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
38. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
39. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
[No Abstract] [Full Text] [Related]
40. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
Young JB
Cardiol Clin; 1995 Aug; 13(3):379-90. PubMed ID: 7585774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
